The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study).

MLA

Deau, Bénédicte, et al. “The Addition of Daunorubicin to Imatinib Mesylate in Combination with Cytarabine Improves the Response Rate and the Survival of Patients with Myeloid Blast Crisis Chronic Myelogenous Leukemia (AFR01 Study).” Leukemia Research, vol. 35, no. 6, June 2011, pp. 777–82. EBSCOhost, https://doi.org/10.1016/j.leukres.2010.11.004.

APA

Deau, B., Nicolini, F. E., Guilhot, J., Huguet, F., Guerci, A., Legros, L., Pautas, C., Berthou, C., Guyotat, D., Cony-Makhoul, P., Gardembas, M., Michallet, M., Hayette, S., Cayuela, J. M., Weiss, I. R., Réa, D., Castaigne, S., Mahon, F.-X., Guilhot, F., & Rousselot, P. (2011). The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study). Leukemia Research, 35(6), 777–782. https://doi.org/10.1016/j.leukres.2010.11.004

Chicago

Deau, Bénédicte, Franck E Nicolini, Joelle Guilhot, Françoise Huguet, Agnès Guerci, Laurence Legros, Cécile Pautas, et al. 2011. “The Addition of Daunorubicin to Imatinib Mesylate in Combination with Cytarabine Improves the Response Rate and the Survival of Patients with Myeloid Blast Crisis Chronic Myelogenous Leukemia (AFR01 Study).” Leukemia Research 35 (6): 777–82. doi:10.1016/j.leukres.2010.11.004.